



AD-A130 158 MUTAGENIC POTENTIAL OF: 4-NITROPHENYL MONOCHLOROMETHYL 1/f  
(PHENYL) PHOSPHINATE (CMP)(U) LETTERMAN ARMY INST OF  
RESEARCH PRESIDIO OF SAN FRANCISCO CA

UNCLASSIFIED L J SAUERS ET AL. MAY 83 LAIR-146 F/G 6/20 NL



END  
DATE  
FILMED  
8-83  
DTIC



MICROCOPY RESOLUTION TEST CHART  
NATIONAL BUREAU OF STANDARDS-1963-A

(12)

INSTITUTE REPORT NO. 146

MUTAGENIC POTENTIAL OF:

4-nitrophenyl monochloromethyl (phenyl) phosphinate (CMP)

LEONARD J. SAUERS, MS, SP5

and

JOHN T. FRUIN, DVM, PhD, COL VC

TOXICOLOGY GROUP,  
DIVISION OF RESEARCH SUPPORT

ADA130158

DTIC FILE COPY

DTIC  
ELECTR  
JUL 7 1983  
S D  
A

MAY 1983

Toxicology Series 50

LETTERMAN ARMY INSTITUTE OF RESEARCH  
PRESIDIO OF SAN FRANCISCO, CALIFORNIA 94129

This document has been approved  
for public release and sale; its  
distribution is unlimited.

83 07 7 047


Toxicology Series 50--Sauers and Fruin

Reproduction of this document in whole or in part is prohibited except with the permission of the Commander, Letterman Army Institute of Research, Presidio of San Francisco, California 94129. However, the Defense Technical Information Center is authorized to reproduce the document for United States Government purposes.

Destroy this report when it is no longer needed. Do not return it to the originator.

Citation of trade names in this report does not constitute an official endorsement or approval of the use of such items.

This material has been reviewed by Letterman Army Institute of Research and there is no objection to its presentation and/or publication. The opinions or assertions contained herein are the private views of the author(s) and are not to be construed as official or as reflecting the views of the Department of the Army or the Department of Defense. (AR 360-5)

  
(Signature and date)

This document has been approved for public release and sale; its distribution is unlimited.

UNCLASSIFIED

SECURITY CLASSIFICATION OF THIS PAGE (When Data Entered)

REPORT DOCUMENTATION PAGE		READ INSTRUCTIONS BEFORE COMPLETING FORM
1. REPORT NUMBER LAIR Institute Report No. 146	2. GOVT ACCESSION NO. A130158	3. RECIPIENT'S CATALOG NUMBER
4. TITLE (and Subtitle) Mutagenic Potential of: 4-Nitrophenyl Monochloromethyl (Phenyl) Phosphinate (CMP)	5. TYPE OF REPORT & PERIOD COVERED Final 10 Aug - 10 Sep 82	
	6. PERFORMING ORG. REPORT NUMBER	
7. AUTHOR(s) Leonard J. Sauers, MS, SP5 John T. Fruin, DVM, PhD, COL VC	8. CONTRACT OR GRANT NUMBER(s)	
9. PERFORMING ORGANIZATION NAME AND ADDRESS US Army Medical Research and Development Command Letterman Army Institute of Research Presidio of San Francisco, CA 94129	10. PROGRAM ELEMENT, PROJECT, TASK AREA & WORK UNIT NUMBERS Project 3/162772A875 WU 304 5	
11. CONTROLLING OFFICE NAME AND ADDRESS US Army Medical Research and Development Command Fort Detrick Frederick, MD 21701	12. REPORT DATE May 1983	
	13. NUMBER OF PAGES 26	
14. MONITORING AGENCY NAME & ADDRESS (if different from Controlling Office)	15. SECURITY CLASS. (of this report) UNCLASSIFIED	
	15a. DECLASSIFICATION/DOWNGRADING SCHEDULE	
16. DISTRIBUTION STATEMENT (of this Report)  THIS DOCUMENT HAS BEEN APPROVED FOR PUBLIC RELEASE AND SALE: ITS DISTRIBUTION IS UNLIMITED.		
17. DISTRIBUTION STATEMENT (of the abstract entered in Block 20, if different from Report)		
18. SUPPLEMENTARY NOTES		
19. KEY WORDS (Continue on reverse side if necessary and identify by block number)  Mutagenicity, Toxicology, Ames Assay, 4-Nitrophenyl Monochloromethyl (Phenyl) Phosphinate (CMP)		
20. ABSTRACT (Continue on reverse side if necessary and identify by block number)  The mutagenic potential of 4-nitrophenyl monochloromethyl (phenyl) phosphinate (CMP*) was assessed by using the Ames Salmonella/Mammalian Microsome Mutagenicity Assay. Tester strains TA 98, TA 100, TA 1535, TA 1537 and TA 1538 were exposed to doses ranging from 1 mg/plate to 3.2 x 10 <sup>-4</sup> mg/plate. It was determined that the test substance did not have mutagenic potential.		
*Code number for compound		

ABSTRACT

The mutagenic potential of 4-nitrophenyl monochloromethyl (phenyl) phosphinate (CMP) was assessed by using the Ames Salmonella/Mammalian Microsome Mutagenicity Assay. Tester strains TA 98, TA 100, TA 1535, TA 1537 and TA 1538 were exposed to doses ranging from 1 mg/plate to  $3.2 \times 10^{-4}$  mg/plate. It was determined that the test substance did not have mutagenic potential.

\*Code number for compound

*10 to the minus 4th power*

KEY WORDS: Mutagenicity, Toxicology, Ames Assay, 4-Nitrophenyl Monochloromethyl (Phenyl) Phosphinate (CMP).

Item	For
TA 98	<input checked="" type="checkbox"/>
TA 100	<input type="checkbox"/>
TA 1535	<input type="checkbox"/>
TA 1537	<input type="checkbox"/>
TA 1538	<input type="checkbox"/>



*A*

PREFACE

TYPE REPORT: Ames Assay GLP Study Report

TESTING FACILITY: US Army Medical Research and Development Command  
Letterman Army Institute of Research  
Presidio of San Francisco, CA 94129

SPONSOR: US Army Medical Research and Development Command  
US Army Medical Research Institute of Chemical Defense  
Aberdeen Proving Ground, MD 21010

PROJECT: 35162772A875 Medical Defense Against Chemical Agents,  
WU 304, Toxicity Testing of Phosphinate Compounds, ✓  
APC TL04

GLP STUDY NUMBER: 82024

STUDY DIRECTOR: COL John T. Fruin, DVM, PhD, VC, Diplomate of  
American College of Veterinary Preventive Medicine

PRINCIPAL INVESTIGATOR: SP5 Leonard J. Sauer, MS

REPORT AND DATA MANAGEMENT: A copy of the final report, study protocols,  
raw data, retired SOPs and an aliquot of the  
test compound will be retained in the LAIR  
Archives.

TEST SUBSTANCE: 4-nitrophenyl monochloromethyl (phenyl) phosphinate (CMP)

INCLUSIVE STUDY DATES: 10 August - 10 September 1982

OBJECTIVE: To determine the mutagenic potential of 4-nitrophenyl  
monochloromethyl (phenyl) phosphinate (CMP) using the Ames  
Assay. Tester strains TA 98, TA 100, TA 1535, TA 1537 and  
TA 1538 were used. The test substance was dissolved in  
dimethyl sulfoxide (DMSO) and this diluent was checked for  
sterility.

#### ACKNOWLEDGMENTS

The authors wish to thank SP4 Lawrence Mullen, BS; Carolyn M. Lewis, MS; and John Dacey; for their assistance in performing the research.

Signatures of Principal Scientists involved  
in the Study

We, the undersigned, believe the study number 82024 described  
in this report to be scientifically sound and the results and  
interpretation to be valid. The study was conducted to comply, to  
the best of our ability, with the Good Laboratory Practice  
Regulations outlined by the Food and Drug Administration.

*Leonard J. Sauers* 23 March 83  
LEONARD J. SAUERS, MS / DATE  
SP5  
Principal Investigator

*John T. Fruin* 23 Mar 83  
JOHN T. FRUIN, DVM, PhD / DATE  
COL, VC  
Study Director



DEPARTMENT OF THE ARMY  
LETTERMAN ARMY INSTITUTE OF RESEARCH  
PRESIDIO OF SAN FRANCISCO, CALIFORNIA 94129

REPLY TO  
ATTENTION OF:

SGRD-JLZ-QA

2 May 83

MEMORANDUM FOR RECORD


SUBJECT: Report of GLP Compliance

I hereby certify that in relation to LAIR GLP study 82024 the following inspections were made:

9 Aug 82  
18 Aug 82  
23 Aug 82

The report and raw data for this study were audited on 27 Apr 83.

Routine inspections with no adverse findings are reported quarterly, thus these inspections are also included in the Oct 82 report to management and the Study Director.

  
NELSON R. POWERS, Ph.D.  
CPT, MSC  
Quality Assurance Officer

## TABLE OF CONTENTS

Abstract.....	i
Preface.....	iii
Acknowledgments.....	iv
Signatures of Principal Scientists.....	v
Report of Quality Assurance Unit.....	vi
Table of Contents.....	vii
BODY OF REPORT	
INTRODUCTION	
Rationale for using the Ames Assay.....	1
Description of Test, Rationale for strain selection.....	1
Description of Strains, History, Methods, and Data.....	2
Objective of Study.....	3
METHODS	
Rationale for Dosage Levels and Response Tabulations.....	3
Test Format.....	4
Statistical Analysis.....	4
Chemical Analysis.....	4
RESULTS and DISCUSSION.....	5
CONCLUSIONS.....	5
RECOMMENDATION.....	5
REFERENCES.....	6
APPENDICES	
Appendix A (Chemical Analysis for CMP).....	8
Appendix B (Tables 1 through 5).....	12
DISTRIBUTION LIST.....	18

MUTAGENIC POTENTIAL OF: 4-nitrophenyl monochloromethyl (phenyl) phosphinate (CMP)  
-Sauers and Fruin

#### Rationale for using the Ames Assay

The Ames Salmonella/Mammalian Microsome Mutagenicity Test is one of a standard bank of tests used by our laboratory for the assessment of the mutagenic potential of a test substance. It is a short-term screening assay, which we use for the prediction of potential mutagenic agents in mammals. It is inexpensive when compared to in vivo tests, yet is highly predictive and reliable in its ability to detect mutagenic activity and therefore carcinogenic probability (1). It relies on basic genetic principles and allows for the incorporation of a mammalian microsomal enzyme system to increase sensitivity through enzymatically altering the test substance into an active metabolite. It has proven highly effective in assessing human risk (1).

#### Description of Test (Rationale for the selection of strains)

The test was developed by Bruce Ames, Ph.D. from the University of California-Berkeley. The test involves the use of several different genetically altered strains of Salmonella typhimurium, each with a specific mutation in the histidine operon (2). The test substance demonstrates mutagenic potential if it is able to revert the mutation in the bacterial histidine operon to the wild type and reestablish prototrophic growth within the test strain. This reversion also can occur spontaneously due to a random mutational event. If, after adding a test substance, the number of revertants is significantly greater than the spontaneous reversion rate, then the test substance physically altered the locus involved in the operon's mutation and is able to induce point mutations (2).

In order to increase the sensitivity of the test system, other mutations in the Salmonella are used (2). To insure a higher probability of uptake of test substance, the genome for the lipopolysaccharide layer (LP) is mutated and, therefore, larger molecules are allowed to enter the bacteria. Each strain has another induced mutation which causes loss of excision repair mechanisms. A mammalian microsomal enzyme system is incorporated since many chemicals are not by themselves mutagenic but have to be activated by an enzymatic process. These microsomal enzymes are obtained from livers of rats induced with Aroclor 1254; the enzymes allow for the expression of the metabolites which would occur in the mammalian system. This activated rat liver microsomal enzyme homogenate is termed S-9.

Description of Strains (History of the strains used method to monitor the integrity of the organisms, and data pertaining current and historical control and spontaneous reversion rates)

The test consists of using five different strains of Salmonella typhimurium that are unable to grow in absence of histidine because of a specific mutation in the histidine operon. This histidine requirement is verified by attempting to grow the tester strains on minimal glucose agar (MGA) plates, both with and without histidine. The dependence on this amino acid is shown when growth occurs only in its presence. The plasmids in strains TA 98 and TA 100 contain an ampicillin resistant R factor. Strains deficient in this plasmid demonstrate a zone of inhibition around an ampicillin impregnated disc. The alteration of the LP layer allows uptake by the Salmonella of larger molecules. If a crystal violet impregnated disc is placed onto a plate containing any one of the bacterial strains, a zone of growth inhibition will occur because the LP layer is altered. The absence of excision repair mechanisms can be determined by using ultraviolet (UV) light. These mechanisms function primarily by repairing photodimers between pyrimidine bases. Exposure of bacteria to UV light will activate the formation of these dimers and cause cell lethality, since excision of these photodimers can not be made. The genetic mutation resulting in UV sensitivity also induces a dependence by the Salmonella to biotin. Therefore, this vitamin must be added. In order to prove that the bacteria are responsive to the mutation process, positive controls are run with known mutagens. If after exposure to the positive control substance, a revertant count is obtained which is greater than twice the spontaneous reversion rate, then the bacteria are adequately responsive. Sterility controls are performed to determine the presence of contamination. Sterility of the test compound is also confirmed in each first dilution. Verification of the tester strains occurs simultaneously with the running of each assay. The value of the spontaneous reversion rate is obtained by using the same inoculum of bacteria that is used in the assay (3).

Strains were obtained directly from Dr. Ames, University of California-Berkeley, propagated and then maintained at  $-80^{\circ}\text{C}$  in our laboratory. Before any substance was tested, quality controls were performed on the bacterial strains to establish the presence of their special features and also to determine the spontaneous reversion rate (2). Records are maintained of all the data to determine if deviations from the set trends have occurred. These records are kept in the archives of the Quality Assurance Unit.

In this series of tests for the detection of mutagenic potential of different agents, we compared the spontaneous reversion values with our own historical values and those cited by Ames et al (2). Our conclusions are based on the spontaneous reversion rate compared to the experimentally induced rate of mutation. When operating effectively, these strains detect substances that cause base pair mutations (TA 1535, TA 100) and frameshift mutations (TA 1537, TA 1538, and TA 98).

#### Objective of Study

The objective of the study is to determine the mutagenic potential of 4-nitrophenyl monochloromethyl (phenyl) phosphinate (CMP) by using the Ames Assay. Tester strains TA 98, TA 100, TA 1535, TA 1537 and TA 1538 were used. The test substance was dissolved in dimethyl sulfoxide (DMSO) and this diluent was checked for sterility.

#### METHODS (3)

##### Rationale for Dosage Levels and Dose Response Tabulations

To insure readable and reliable results, a sublethal concentration of the test substance had to be determined. This toxicity level was found by using MGA plates, various concentrations of the substance, and approximately  $10^8$  cells of TA 100 per plate, unless otherwise specified. Top agar containing trace amounts of histidine and biotin were placed on MGA plates. TA 100 was used because it is the most sensitive strain. Strain verification was confirmed on the bacteria, along with a determination of the spontaneous reversion rate. After incubation, the growth was observed on the plates. (The auxotrophic Salmonella will replicate a few times and potentially express a mutation. When the histidine and biotin supplies are exhausted, only those bacteria that reverted to the prototrophic phenotype will continue to reproduce and form macrocolonies; the remainder of the bacteria comprises the background lawn. The minimum toxic level is defined as the lowest serial dilution at which decreased macrocolony formation, below that of the spontaneous revertant rate, and an observable reduction in the density of the background lawn occurs.) A maximum dose of 1 mg/plate is used when no toxicity is observed. The densities were recorded as normal, slight, and no growth.

### Test Format

After we validated our bacterial strains and determined the optimal dosage of the test substance, we began the Ames Assay. In the actual experiment, 0.1 ml of the particular strain of Salmonella ( $10^8$  cells) and the specific dilutions of the test substance were added to 2 ml of molten top agar, which contained trace amounts of histidine and biotin. Since survival is better from cultures which have just passed the log phase, the Salmonella strains are used 16 hours (maximum) after initial inoculation into nutrient broth. The dose of the test substance spanned a 1000-fold, decreasing from the minimum toxic level by a dilution factor of 5. All the substances were tested with and without S-9 microsomal fraction. The optimal titer of the S-9 was determined and 0.5 ml was added to the molten top agar. After all the ingredients were added, the top agar was mixed, then overlaid on minimum glucose agar plates. These plates contained 2% glucose and Vogel Bonner "E" Concentrate (4). The water used in this medium and all reagents came from a polymetric system. Plates were incubated, upside down in the dark at  $37^{\circ}$  C for 48 hours. Plates were prepared in triplicate and the average revertant counts were recorded. The corresponding number of revertants obtained was compared to the number of spontaneous revertants; the conclusions were recorded statistically. A correlated dose response is considered necessary to declare a substance as a mutagen. Commoner (5), in his report, "Reliability of Bacterial Mutagenesis Techniques to Distinguish Carcinogenic and Non-Carcinogenic Chemical," and McCann et al (1) in their paper, "Detection of Carcinogens as Mutagen in the Salmonella/Mammalian Microsome Mutagenicity Test: Assay of over 300 Chemicals," have concurred on the test's ability to detect mutagenic potential.

### Statistical Analysis

Quantitative evaluation was ascertained by the method of Ames et al (2). They assumed that a compound which causes twice the spontaneous reversion rate and a correlated dose response is mutagenic.

### Chemical Analysis

Information on the chemical analysis of CMP appears in Appendix A.

## RESULTS AND DISCUSSION

Throughout this report, the test substance will be referred to by its code number.

<u>Substance</u>	<u>Code No.</u>
4-Nitrophenyl Monochloromethyl (Phenyl) Phosphinate	CMP

On 10 August 1982 the toxicity level determination was performed for CMP. Results appear in Tables 1 to 5, Appendix B. For this experiment, all sterility, strain verification and negative controls were normal (Table 1). No toxicity was observed at the 1 mg/plate concentration (Table 2). Therefore, we use 1 mg/plate as the highest dose.

On 18 August 1982, the Ames Assay was performed on the test substance. In this assay normal results were observed for all sterility and strain verification controls (Table 3). Normal results were also observed for all positive and negative controls (Table 4). Following exposure of the bacteria to the test substance, no incidences of mutagenicity were observed (Table 5).

## CONCLUSIONS

The Ames Assay is able to detect frameshift and basepair mutagenic potential. Our results show no evidence of such potential. Therefore on the basis of the Ames Assay, CMP both in the presence and absence of metabolic activation is not mutagenic at the levels tested.

## RECOMMENDATION

CMP should be tested using other toxicological assays, if efficacy tests prove this compound to be a promising antidote.

REFERENCES

1. McCann JE, Choi E, Yamasaki E, Ames BN. Detection of carcinogens as mutagens in the Salmonella/microsome test: Assay of 300 chemicals. Proc Nat Acad Sci, USA 1975;72:5135-5139.
2. Ames BN, McCann J, Yamasaki E. Methods for detection carcinogens and mutagens with Salmonella/mammalian microsome mutagenicity test. Mutation Res 1975;31:347-364.
3. LAIR SOP OP-STX-1, Ames Salmonella/mammalian microsome mutagenicity test, 15 February 1982.
4. Vogel HJ, Bonner DM. Acetylornithinase of E. coli: Partial purification and some properties. J Biol Chem 1956;218:97-106.
5. Commoner B. Reliability of the bacterial mutagenesis techniques to distinguish carcinogenic and non-carcinogenic chemicals. EPA 600/1 76-022, 1976.

	Page
Appendix A, Chemical Analysis.....	8
Appendix B, Tables 1-5.....	11

APPENDICES


CHEMICAL ANALYSIS

Chemical Name: 4-nitrophenyl monochloromethyl (phenyl) phosphinate (CMP)

CAS: none

Molecular Formula:  $C_{13}H_{11}ClNO_4P$

Molecular Structure:



Elemental Analysis:

	Calculated	Found
C	50.09	49.95
H	3.56	3.57
N	4.50	4.47
Cl	11.38	11.26
P	9.94	10.00

Molecular Weight: 311.67

Stability: base sensitive

Appearance: white crystalline solid

Mp. obs: 77-78.5 C

IR spectra: attached

Manufacturer: Ash Stevens, Detroit Research Park,  
5861 John C. Lodge Freeway,  
Detroit, Michigan 48202

Manufacture Lot No.: MP-07-201



LIST OF TABLES

	Date	Page
Table 1 Strain Verification for Toxicity Level Determination	10 Aug 82	12
Table 2 Toxicity Level Determination	10 Aug 82	13
Table 3 Strain Verification Control	20 Aug 82	14
Table 4 Positive and Negative Control	20 Aug 82	15
Table 5 Number of Revertants/Plate	20 Aug 82	16

APPENDIX B

TABLE 1  
STRAIN VERIFICATION FOR TOXICITY LEVEL DETERMINATION

Strains	Histidine Requirement	Ampicillin Resistance	UV	Sensitivity to Crystal Violet	Sterility Control	Response (1)
100	NG	G	NG	14.5 mm	NG	+
1537	NG	14.5 mm	NG	13.2 mm	NG	+
WT	G	NA	G	G	NA	+

STERILITY CONTROL

His-Bio Mix Initial: NG End: NG MGA Plate: NG  
 Top Agar Initial: NG End: NG  
 Diluent: NG Nutrient Broth: NG  
 Test Compound (a) CMP-NG (b) CHR6-NG (c) NA (d) NA (e) NA  
 G = Growth NC = No Growth NT = Not Tested NA = Not Applicable WT = Wild Type

Spontaneous Revertants: TA 100, No S-9 109, 95, 81, 97, 121, 109 Average: 102

(1) + = expected response - = unexpected response

Study Number: 82024 Date: 10 Aug 82 By: Sauers



TABLE 3

STRAIN VERIFICATION CONTROL

Strains	Histidine Requirement	Ampicillin Resistance	UV	Sensitivity to Crystal Violet	Sterility Control	Response (1)
98	NG	G	NG	12 mm	NG	+
100	NG	G	NG	12 mm	NG	+
1535	NG	NA	NG	14 mm	NG	+
1537	NG	14 mm	NG	13 mm	NG	+
1538	NG	NA	NG	12 mm	NG	+
WT	G	NA	G	G	NA	+

STERILITY CONTROL

His-Bio Mix Initial: NG End: NG Diluent: NG  
 Top Agar Initial: NG End: NG MGA Plate: NG  
 S-9 Mix Initial: NG End: NG Nutrient Broth: NG  
 Test Compound (a) CHR4-NG (b) CHR6-NG (c) CMP-NG (d) NA (e) NA (f) NA  
 G = Growth NG = No Growth NT = Not Tested NA = Not Applicable WT = Wild Type  
 Study Number: 82024 By: Sauers (1) + = expected response  
 Date: 20 Aug 82 - = unexpected response

TABLE 4

NUMBER OF REVERTANTS/PLATE

Compd.	Amount of Compd. Added	S-9 Added	98	100	Strain No.	
					1535	1537
AF	2 ug/plate	yes	(648, 518, 591) 586	(337, 377, 285) 333	(579, 677, 449) 568	1538
BP	2 ug/plate	yes	( 94, 73, 90) 86	(350, 361, 357) 356	( 37, 54, 27) 39	( 76, 52, 87) 72
AA	2 ug/plate	yes	(612, 803, 656) 690	(999, 831, 934) * 921	(150, 161, 171) 161	(909, 919, 721) 850
MMNG	2 ug/plate	no		(871, 999, 999) *		
	20 ug/plate	no			(999, 999, 999) *	

Spontaneous Reversion Rate

before	yes	( 18, 18, 25) ( 16, 19, 18)	( 89, 91, 74) ( 93, 92, 89)	( 9, 8, 8) ( 17, 13, 9)	( 3, 4, 5) ( 6, 5, 3)	( 15, 19, 11) ( 9, 12, 22)
after		19	88	11	4	15
before	no	( 11, 11, 23) ( 16, 17, 25)	( 77, 60, 69) ( 63, 87, 75)	( 11, 12, 7) ( 15, 10, 16)	( 3, 4, 7) ( 4, 3, 6)	( 14, 7, 10) ( 13, 15, 10)
after		17	72	12	5	12

\* 999 = signifies a value greater than 1000

Study Number: 82024Date: 20 Aug 82 By: Sauers, Kellner, Lewis, Dacey

TABLE 5  
NUMBER OF REVERTANTS/PLATE

Compd.	Amount of Compd. Added	S-9 Added	98	100	Strain Number		
					1535	1537	
CMP	1 mg/plate	no	( 10, 7, 10) 9	( 50, 64, 62) 59	( 9, 7, 9) 8	( 3, 4, 3) 3	( 8, 8, 12) 9
		yes	( 17, 10, 7) 11	( 54, 70, 72) 65	( 5, 5, 5) 5	( 2, 4, 3) 3	( 19, 11, 16) 15
CMP	0.2 mg/plate	no	( 10, 10, 14) 11	( 50, 69, 65) 61	( 11, 8, 7) 9	( 3, 5, 6) 5	( 8, 9, 11) 9
		yes	( 14, 14, 21) 16	( 64, 77, 68) 70	( 10, 8, 7) 8	( 5, 6, 2) 4	( 12, 8, 17) 12
CMP	0.04 mg/plate	no	( 7, 13, 12) 11	( 73, 53, 61) 62	( 7, 17, 10) 11	( 2, 6, 4) 4	( 5, 19, 11) 12
		yes	( 25, 19, 18) 21	( 71, 64, 62) 66	( 8, 5, 7) 7	( 5, 4, 4) 4	( 13, 13, 19) 15
CMP	0.008 mg/plate	no	( 12, 10, 10) 11	( 55, 54, 50) 53	( 11, 7, 8) 9	( 4, 3, 2) 3	( 5, 11, 14) 10
		yes	( 11, 14, 15) 13	( 70, 65, 54) 63	( 13, 13, 12) 13	( 6, 8, 5) 6	( 22, 14, 15) 17

-continued

Study Number: 82024 Date: 20 Aug 82 By: Sauers, Kellner, Lewis, Dacey

TABLE 5 (concluded)

NUMBER OF REVERTANTS/PLATE

Compd.	Amount of Compd. Added	S-9 Added	98	100	Strain Number		
					1535	1537	
CMP	0.0016 mg/plate	no	( 13, 7, 11) 10	( 63, 67, con) 65	( 17, 7, 12) 12	( 2, 2, 3) 3	( 12, 7, 6) 8
		yes	( 12, 20, 14) 15	( 61, 72, 75) 69	( 9, 9, 8) 9	( 4, 4, 6) 5	( 14, 15, 14) 14
CMP	0.00032 mg/plate	no	( 25, 21, 15) 20	( 98, 93, 131) 107	( 10, 13, 10) 11	( 3, 3, 4) 4	( 7, 8, 11) 9
		yes	( 14, 11, 12) 12	( 65, 79, 57) 67	( 16, 9, 13) 13	( 4, 2, 4) 4	( 18, 12, 10) 13

con = plate value disregarded due to contamination

Study Number: 82024 Date: 20 Aug 82 By: Sauers, Kellner, Lewis, Dacey

OFFICIAL DISTRIBUTION LIST

Commander  
US Army Medical Research  
and Development Command  
ATTN: SGRD-RMS/Mrs. Madigan  
Fort Detrick, Frederick MD 21701

Defense Technical Information Center  
ATTN: DTIC-DDA (12 copies)  
Cameron Station  
Alexandria VA 22314

Director of Defense Research and Engineering  
ATTN: Assistant Director, Environmental  
and Life Sciences  
Washington DC 20301

The Surgeon General  
ATTN: DASG-TLO  
Washington DC 20314

HQ DA (DASG-ZXA)  
WASH DC 20310

Commandant  
Academy of Health Sciences  
ATTN: HSHA-CDM  
Fort Sam Houston TX 78234

Assistant Dean  
Institute and Research Support  
Uniformed Services University  
of Health Sciences  
6917 Arlington Road  
Bethesda MD 20014

Commander  
US Army Environmental Hygiene Agency  
Aberdeen Proving Ground MD 21070

US Army Research Office  
ATTN: Chemical and Biological Sciences  
Division  
P.O. Box 1221  
Research Triangle Park NC 27709

Biological Sciences Division  
Office of Naval Research  
Arlington VA 22217

Director of Life Sciences  
USAF Office of Scientific Research (AFSC)  
Bolling AFB  
Washington DC 20332

Director  
Walter Reed Army Institute of Research  
Washington DC 20307

Commander  
US Army Medical Research Institute  
of Infectious Diseases  
Fort Detrick, Frederick MD 21701

Commander  
US Army Research Institute  
of Environmental Medicine  
Natick MA 01760

Commander  
US Army Institute of Surgical Research  
Brooke Army Medical Center  
Fort Sam Houston TX 78234

Commander  
US Army Medical Bioengineering  
Research and Development Laboratory  
Fort Detrick, Frederick MD 21701

Commander  
US Army Aeromedical Research Laboratory  
Fort Rucker AL 36362

Commander  
US Army Research Institute  
of Chemical Defense  
Aberdeen Proving Ground  
Edgewood Arsenal MD 21010

Commander  
Naval Medical Research Institute  
National Naval Medical Center  
Bethesda MD 20014

Commander  
USAF School of Aerospace Medicine  
Aerospace Medical Division  
Brooks Air Force Base TX 78235

END

DATE  
FILMED

8 - 83

DTIC